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Tumor-Associated Alterations in Caspase-14 Expression in
Epithelial Malignancies
Maryla Krajewska,1Hoguen Kim,2 Eunah Shin,2 Susan Kennedy,3 MichaelJ. Duffy,4 Yick F. Wong,5
DavidMarr,6 JowitaMikolajczyk,1Ahmed Shabaik,7 IvoMeinhold-Heerlein,8 Xianshu Huang,1
Steven Banares,1Hirad Hedayat,1John C. Reed,1and Stan Krajewski1
Abstract Purpose:Caspase-14 is unique amongcaspase family proteases in that its proteolyticprocessing
has been principally associated with epithelial cell differentiation rather than apoptosis or inflam-
mation.We investigated caspase-14 expression in several types of humanepithelialmalignancy by
immunohistochemistry, correlating results with stage, histologic grade, and patient survival.
Experimental Design:Tumor-associated alterations in caspase-14 expression were observed
for cervical, ovarian, breast, gastric, and colon cancers.
Results: In cervical (n = 445), ovarian (n = 91), and colon (n = 106) specimens, expression
of caspase-14 was significantly reduced in cancers compared with normal epithelium. Decreases
in caspase-14 immunopositivity correlated with the histologic progression of cervical cancer
(P < 0.0001, ANOVA). In localized gastric cancers, caspase-14 immunostaining was significantly
lower in poorly differentiated tumors compared with well-differentiated tumors (P = 0.02,
Pearson’sm2 analysis). Lower caspase-14 expressionwas associatedwith advancedclinical stage
in ovarian cancer (P = 0.04, ANOVA) and with shorter overall survival among ovarian cancer
patients with serous tumors (n = 62) in both univariate (P = 0.005) and multivariate (P = 0.03)
analysis. Lower caspase-14 expression correlated with shorter overall survival among patients
withT3N0M0 stage gastric cancers (n = 94; P = 0.006, log-rank test). In contrast to cervical,
ovarian, and colon cancers, caspase-14 expression was increased in ductal carcinoma in situ
and invasive cancers comparedwith normalmammary epithelium (P = 0.001, t test).
Conclusions: The findings reveal tumor-specific alterations in caspase-14 expression and
suggest that differences in its expression may define subsets of epithelial cancers with distinct
clinical behaviors.
Caspases are aspartate-directed cysteine proteases (1), best
known for their roles in apoptosis. Many of these proteases
cleave and activate other caspases, thus constituting a highly
regulated protease network. Eleven caspases have been identi-
fied in humans, and they can be divided into three groups
based on the domain composition and function (2). Upstream
initiator caspases possess long prodomains containing caspase
recruitment domains or death effector domains preceding their
catalytic domains and trigger apoptosis or process proinflam-
matory cytokines. These apoptotic proteases include caspase-2,
caspase-8, caspase-9, and caspase-10, whereas inflammatory
proteases include caspase-1, caspase-4, and caspase-5 (reviewed
in ref. 3). Caspase-3, caspase-6, and caspase-7 constitute a
subgroup of downstream effector proteases responsible for
apoptosis. These proteins contain short prodomains (3).
Caspase-14 has a very short prodomain (4–6). Based on a
phylogenetic analysis, the catalytic domain of caspase-14 is
most closely related to the cytokine-activating caspases (2). In
contrast to the other short prodomain caspases, caspase-14 fails
to undergo proteolytic processing in cultured cells following
treatment with apoptosis inducers (5). Also, no substrates of
this caspase have been described to date (7). Caspase-14 is
highly expressed in embryonic tissues. Expression of caspase-14
mRNA in several adult organs was reported by Ahmad et al. (4),
but was claimed to be limited predominantly to epidermis by
others (5, 6). Subsequent studies showed transcriptional
regulation of caspase-14 expression in simple and complex
epithelia (8, 9). Caspase-14 processing was observed during
terminal differentiation of epidermal keratinocytes (7, 10), and
the determined processing site between Ile152 and Lys153
distinguishes caspase-14 from other caspases that are cleaved
at aspartate residues (11). Caspase-14 expression is reportedly
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suppressed in human epidermis when terminal differentiation
of keratinocytes is blocked by retinoic acid (12). Regulation of
caspase-14 expression by retinoids analogous to proteins of
terminal keratinocyte differentiation suggests its involvement in
skin barrier formation (12). Also, low expression of caspase-14
in psoriatic skin was elevated by vitamin D3 treatment,
enhancing caspase-14 processing in organotypic skin cultures
(13). In normal stratum corneum and parakeratotic skin,
procaspase-14 is converted to proteolytically processed sub-
units during terminal keratinocyte differentiation (14).
Recently, peptidolytic activity of recombinant caspase-14 was
reported to be induced by granzyme B cleavage when incubated
with kosmotropic salts (15), suggesting that the search for
potential substrates of caspase-14 should be focused on
proteins of the outermost skin layers (14). Thus, caspase-14 is
unique among caspase family proteins and may have a different
cellular role than related proteins.
The predominantly epithelial expression of caspase-14, and
its implicated role in differentiation, evoked our interest in
assessing a potential role of this caspase in the malignant
transformation of human epithelial cells. This report is the first
to describe transformation-associated changes in caspase-14
expression in several types of human malignancies.
Materials andMethods
Patient specimens. Tissue microarrays containing cervical specimens
were obtained from the Department of Pathology, Yonsei University
(Seoul, Korea). Tissue samples from patients presented between 1998
and 2001 included the cervical intraepithelial neoplasia 1 (CIN1; n =
47), CIN2 (n = 46), CIN3 (n = 137), invasive squamous cell carcinoma
(n = 109), and normal cervical epithelium adjacent to the transformed
cells (n = 262). In addition, 26 low-grade and 37 high-grade CIN as
well as 43 invasive cervical squamous cell carcinoma specimens were
obtained from the Prince of Wales Hospital, Hong Kong. Investigation
of specimens for research purposes was approved by the institutional
ethics review board in the Chinese University of Hong Kong. Informed
consent was obtained from all subjects (16).
A total of 180 nonconsecutive cases of localized gastric cancer were
provided by the Department of Pathology at Yonsei University
Medical Center. All gastric specimens, derived from patients who
presented to the hospital in 2001, were independently reviewed and
classified by two pathologists, and areas containing malignant or
normal (n = 99) gastric epithelium were marked for generation of
tissue microarrays. The clinicopathologic parameters, such as tumor-
node-metastasis (TNM) stage, tumor differentiation, histomorphologic
architecture (according to Lauren’s classification), and survival data, were
available for statistical analyses. Among the investigated cases, patients
with T2N0M0 stage constituted 48% (n = 86) of the cohort, whereas
52% (n = 94) represented T3N0M0 cancers. The median follow-up
period was 7.9 years.
Early-stage colorectal carcinoma specimens were obtained from the
Department of Pathology at Yonsei University under institutional
review board approval. Tissue samples included 106 nonconsecutive
primary tumors derived from patients who presented between 1986
and 1996 with Dukes’ B stage [stage II disease, as defined by
American Joint Committee on Cancer and Union Internationale
Contre le Cancer (AJCC/UICC) criteria]. Patients with Dukes’ stage
B2 (T3N0M0) constituted 91% of the cohort, whereas 9% represented
Dukes’ B3 (T4N0M0) cancer. None of these patients received chemo-
therapy. Clinical data represent a median follow-up of 66 months.
Patients with double primary malignancy in other organs and a case
of familial adenomatous polyposis coli were excluded from the
analysis. Only patients whose primary cause of death was due to
colorectal carcinoma were eligible for inclusion. Individuals whose
tumors had positive circumferential margins were not included in
the study. We defined right-sided tumors as those originating
proximal to the splenic flexure, and left-sided as those arising distal
to this site.
Ovarian cancer specimens derived from 91 patients presenting to the
Department of Gynecology and Obstetrics of the University of Freiburg/
Germany between 1993 and 1998 were included in this study. Clinical
data, including survival and chemoresponse data, were available until
July 2000, representing a median follow-up of 35 months. This patient
cohort was characterized previously elsewhere (17, 18).
Tissue specimens containing normal mammary epithelium (n = 16),
in situ breast carcinomas (n = 23), and 121 invasive breast tumors,
representing the ductal (n = 103), lobular (n = 15), and mucinous
(n = 3) histologic subtypes were obtained from St. Vincent’s Hospital in
Dublin, Ireland, for tissue microarray generation. The specimens were
derived from women who presented in 2001 with symptomatic stage I
to III breast cancers, using residual pathologic materials remaining after
diagnostic and hormone receptor determination.
Tissue preparation. Normal colon and ovarian tissues for immu-
nohistochemistry analysis were derived from human biopsy and
autopsy material obtained under Institutional Review Board approval
(Department of Pathology, University of California-San Diego, San
Diego, CA). The tissues were prepared for paraffin embedding, as
described elsewhere (19).
Tissue microarrays. Tissue microarrays were produced for all
investigated tumors and tissues, as described previously (18).
Antibodies. Generation of rabbit polyclonal caspase-14 antiserum
(AR-76), using affinity-purified His6-tagged recombinant human
caspase-14 full-length protein as immunogen, was described previously
(20). The monospecificity of the antiserum was confirmed by SDS-
PAGE/immunoblot analysis (20). For chicken polyclonal caspase-14
antiserum (ACy-24), similar immunogen preparation and immuniza-
tion protocols were applied. However, the amount of immunogen per
immunization did not exceed 100 Ag/500 AL physiologic salt solution
and the immunization time was shorter (6 months) compared with that
of rabbits. Egg collection started during the second month of
immunization and was repeated after every month of boosting for
the total period of 6 months. Test bleeds were taken from the wing
artery. Termination of the immunization cycle was done by heart
puncture exsanguination of anesthetized animals.
Immunohistochemistry. Immunohistochemistry procedure applied
to dewaxed tissue sections was described elsewhere (21). Antisera
specific for caspase-14 were applied at 1:4,000 (AR-76) and 1:10,000
(v/v; ACy-24). To verify specificity of the results, the immunostaining
procedure was done in parallel using preimmune serum or caspase-14
antiserum preabsorbed with 5 to 10 Ag/mL of recombinant protein
immunogen. The immunostaining scoring system was described
previously (18).
For double-labeling experiments, tissue sections were stained using
caspase-14 rabbit polyclonal antiserum and mouse monoclonal anti-
proliferating cell nuclear antigen (PCNA) antibody (DAKOCytomation,
Inc., Burlingame, CA) in conjunction with species-specific secondary
antibodies, as described elsewhere (20).
Cell isolation, culture, and generation of cell microarray. Established
tumor cell lines were cultured as previously described (22), harvested
after fixation, and embedded in paraffin to be arrayed into a tissue
microarray block for immunohistochemical screenings. The cell lines
included the National Cancer Institute-60 tumor cell line panel (23)
plus 14 additional cancer cell lines maintained in our laboratory: seven
breast cancer cell lines (231, BT474, HS574, A1N4, 10A, 468, and
ZR751), five prostate cancer lines (PPC1, ALVA31, JCA1, LNCaP, and
Tsu-PRL), the lymphoma line RS11846, and the endometrium
carcinoma line Ishikawa.
Immunoblotting. Human cell lines and specimens derived from
normal and malignant human tissues with high ratios of cancer cells
relative to stroma (>70%) were selected for immunoblotting analysis.
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The protein lysate preparation, immunoblotting procedure, and antigen
detection were described previously (24).
Microsatellite instability. Specimens were analyzed for microsatel-
lite instability by PCR amplification of microsatellite markers using
DNA from snap-frozen tumor specimens. Extracted DNAs from tumors
and matched normal mucosae were PCR amplified at six microsatellite
loci to evaluate the microsatellite instability. The markers included the
National Cancer Institute–recommended panel of five markers, plus
BAT40 (25). PCR products were separated in 6% polyacrylamide gels
containing 5.6 mol/L urea, followed by autoradiography. In tumors
with microsatellite instability, additional bands were found relative to
the normal alleles. Microsatellite instability in three or more markers of
which more than two mononucleotide repeat markers were included
was classified as MSI-H, whereas all others were classified as micro-
satellite stable (MSS).
Statistical analysis. Data were analyzed using the STATISTICA
software package (StatSoft). The Student’s t test was applied to
characterize protein distribution in normal versus malignant tissues.
Differences in the distribution of variables were tested using the
Pearson’s m2 statistics for categorical variables and the ANOVA test for
continuous variables. Pearson’s correlation coefficients were calculated
to assess whether there were relationships between the caspase-14 and
PCNA protein levels. To perform survival analysis, the immunostaining
data were dichotomized at the median, comparing the clinical outcome
for patients whose tumor immunoscores or immunopercentages were
above the median with those below the median. Overall survival,
defined as the time from study entry to death, was determined in
univariate survival analysis using the Kaplan-Meier method. Log-rank
test was used for correlation of immunostaining data with the patient
survival. Multivariate Cox proportional hazards models were fitted to
the data to assess which biomarkers were independently associated with
overall survival. All factors that had prognostic significance when
considered alone (P < 0.05) were entered into a multiple regression
analysis whereby hazard ratios and significance levels were estimated.
In backward selection, a factor that was not statistically significant was
removed from the model until all remaining factors were significant.
The 95% confidence intervals for the hazard ratios were calculated by
the formula exp[b F 1.960 SE (b)].
Results
Characterization of caspase-14 antibodies and immunoblot
analysis of normal human tissues and tumor cell lines. To
characterize the specificity of the two polyclonal antibodies,
immunoblot analysis was done using recombinant caspase
family proteins generated in bacteria and using lysates from
human tissues and cell lines (Fig. 1).
As reported by others, procaspase-14 was detected in lysates
of human epidermis as a 28 kDa protein, and the respective
cleavage products were visualized at 11 and 17 kDa by
immunoblot analysis (10, 14). Similarly, analysis of human
cancer cell lines detected caspase-14 proform (28-29 kDa) and
caspase-14-p17 (8).
Unlike other human caspases, caspase-14 does not undergo
catalytic processing under the unusually high concentrations of
expression in Escherichia coli (15). Thus, in contrast to caspase-
3, caspase-6, caspase-7, caspase-8, caspase-9, and caspase-10,
which generated large and small subunits of the catalytic
domain, recombinant human and mouse caspase-14 was
obtained as an unprocessed full-length protein (15). Both
rabbit (AR-76) and chicken (AC24y) antibodies raised against
purified recombinant human procaspase-14 were determined
to be specific for caspase-14, lacking cross-reactivity with other
caspase family members (ref. 20) and Fig. 1A, respectively.
Reprobing of the blot with His-tag antibody showed loading of
Fig. 1. Characterization of caspase-14
antibodies. A , recombinant purified
caspases were subjected to SDS-PAGE/
immunoblot analysis, using chicken
antibody to caspase-14 (AC-24Y).
The difference in gel mobility of human and
mouse caspase-14 is consistent with the
lengths of these proteins of 242 and 257
amino acids, respectively. B, reprobing of
the blot with His-tag antibody showed
loading of comparable amounts of all
proteases.C,1to 500 ngof the recombinant
human or murine caspase-14 protein were
analyzed by SDS-PAGE/immunoblotting
using rabbit antibody to caspase-14
(AR-76).D, lysates from human tissues or
cell extracts were normalized for total
protein content (50 Ag/lane) and subjected
to SDS-PAGE/immunoblot analysis using
1:5,000 (v/v) caspase-14 antiserum
(AR-76). Antibody detectionwas
accomplished using an enhanced
chemiluminescencemethod. As a control,
15 ng of recombinant human
caspase-14-His6 protein was also
included in both gels.
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comparable amounts of all recombinant proteases (Fig. 1B).
Evaluation of different concentrations of recombinant caspase-
14 protein showed that as little as 1 ng was easily detected by
immunoblotting using both antibodies (Fig. 1C and data not
shown).
To further characterize caspase-14 expression, we analyzed
lysates from human tissues and extracts from human cell lines
by immunoblotting. Both chicken and rabbit antibodies
detected caspase-14 proenzyme as a band of f29 kDa in
human epidermis (AR-76 and data not shown; Fig. 1D and E),
brain (AR-76; Fig. 1D), cervical and mammary epithelium
(AR-76; Fig. 1E), consistent with prior reports showing caspase-
14 expression in complex and simple epithelia (8, 15) and in
the central nervous system (20). These antisera also reacted
with processed forms of caspase-14 in epidermis consistent
with prior reports. Interestingly, processed caspase-14 was also
detected in brain tissue lysates (AR-76; Fig. 1D). Reprobing the
same blot with an antibody recognizing a-actin confirmed
loading of equivalent amounts of total protein from all
samples.
By immunoblotting, full-length caspase-14 protein was also
detected in prostate (PC-3), breast (MCF-7), ovarian (OVCAR-3),
and colon (HCC-2998) cancer cell lines but not in a cervical
cancer line (HeLa; Fig. 1D). Altogether, these results confirm the
specificity of our polyclonal antisera for caspase-14.
Immunohistochemical analysis of caspase-14 expression in
human malignancies. Caspase-14 protein expression was
investigated in cohorts of patients with cervical, gastric,
colorectal, ovarian, and breast cancer. All quantitative data
were generated with our rabbit antibody but comparable
findings were observed at a qualitative level using the chicken
antibody.
Cervical cancer. Tissue microarrays containing cervical
specimens derived from Asian women diagnosed with CIN1
(low-grade squamous intraepithelial lesions; mild dysplasia;
n = 47), CIN2 (high-grade squamous intraepithelial lesion;
moderate dysplasia; n = 46), CIN3 (high-grade squamous
intraepithelial lesion; severe dysplasia-carcinoma in situ ; n =
137), and invasive squamous cell carcinoma (n = 109) were
stained for caspase-14. Normal cervical epithelium adjacent to
the transformed cells was available for each histologic entity
(n = 230) for all patients in the precancerous groups, and 32 of
109 in women diagnosed with invasive cancer. The highest
levels of caspase-14, measured both by immunopercentage and
immunoscore (not shown), were observed in the normal
epithelium of the exocervix (Fig. 2A and F). In normal cervical
squamous epithelium, caspase-14 staining was found mostly in
the midzone layer (stratum spongiosum), but was entirely
absent from the basal/parabasal cell layer, where mitotically
active cells are known to reside, suggesting induction of
caspase-14 expression with differentiation. Caspase-14 expres-
sion rapidly declined during precancerous stages of malignant
transformation, decreasing progressively as the histologic
severity of the atypia advanced from CIN1 to CIN3 (Fig. 2B-
D, F). The expression of caspase-14 was nearly absent in CIN3
and invasive squamous cell carcinoma (Fig. 2E, F). In contrast
to caspase-14, immunoreactivity for cell proliferation marker
PCNA was barely detectable in normal cervical epithelium
and significantly increased with malignant transformation
(Fig. 2F). Thus, decreased expression of caspase-14 correlated
inversely with increasing PCNA levels during the neoplastic
process (r = 0.62 for comparison of immunopercentage data,
P < 0.0001).
Our observations were confirmed by immunostaining results
obtained on cervical specimens derived from the Prince of
Wales Hospital in Hong Kong, showing significantly higher
caspase-14 expression in low grade CIN (n = 26) compared
with high-grade CIN (n = 37) and cervical squamous cell
carcinoma (n = 43; P = 0.001).
Gastric cancer. Archival gastric specimens from 180 Asian
patients who underwent surgical resection for localized gastric
cancer were immunohistochemically analyzed. The primary
selection criteria were the availability of formalin-fixed and
paraffin-embedded blocks and sufficient clinical follow-up for
tumor-specific survival analysis. Using a tissue microarray
approach, the expression of caspase-14 was investigated
immunohistochemically in T2N0M0 (n = 86) and T3N0M0
(n = 94) primary gastric carcinomas in relation to patient
clinicopathologic features. Caspase-14 was not expressed in the
gastric surface epithelium, but positive immunostaining was
found in glands deep within the gastric mucosa (not shown).
The location of caspase-14 was heterogenous in gastric cancers.
When present, the subcellular location of caspase-14 immu-
nostaining in tumors was predominantly cytosolic. However,
38% of diffuse and 10% of intestinal tumors contained both
cytosolic and nuclear staining. Ultrastructural analysis recently
revealed both cytosolic and nuclear caspase-14 labeling in
human epidermis (26). In another study, nuclear translocation
of caspase-14 was found to be associated with barrier formation
in normal epidermal cells and was markedly reduced in areas of
parakeratosis where abnormally high epidermal proliferation
occurs (27).
In the investigated cohort, the expression of caspase-14 was
significantly associated with histologic architecture and cellular
differentiation of adenocarcinomas. As assessed by immuno-
percentage and immunoscore, caspase-14 was expressed at
higher levels in well-differentiated (Fig. 3A) compared with
poorly differentiated tumors (48 F 8.3% versus 24 F 3.5%, P =
0.004; 58 F 11.1% versus 35 F 5.9%, P = 0.02; Fig. 3B) and in
intestinal-type compared with diffuse-type cancers (P = 0.0001,
P = 0.006, respectively; Fig. 3C). Tumors containing signet ring
cells contained lower levels of caspase-14 than non–signet ring
cell tumors (not shown). Unlike cervical cancers, increased
content of caspase-14 correlated positively with elevated PCNA
in gastric carcinomas (r = 0.21 for comparison of immuno-
percentages, P = 0.01). In contrast, no association was found
between caspase-14 protein expression and prominent lym-
phoid infiltration or mucin content in tumors (not shown).
With respect to clinical outcome, patients with stage T3N0M0
tumors that contained higher levels of caspase-14 (dichoto-
mized at the median) had significantly longer overall survival
(P = 0.04 for immunopercentage and P = 0.006 for immuno-
score; Fig. 3D). However, this association with survival was not
observed for T2N0M0 stage patients (not shown). In multivar-
iate Cox proportional hazards analysis, caspase-14 remained
significant as an independent prognostic factor for the T3M0N0
stage patients (Table 1).
Colon cancer. Tissue microarrays were constructed using
primary tumor specimens derived from a cohort of noncon-
secutive 106 patients with stage II colorectal carcinoma, who
were treated by surgical resection with curative intent. Of
the 106 selected cases, 63 patients survived without recurrence,
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7 patients had recurrent disease, and 36 patients died from
colorectal carcinoma. Thus, whereas not an unbiased sequential
case series, the survival profile of this cohort closely resembles
that of a random population of stage II colorectal carcinoma
patients, with 72.5% of individuals alive at 5 years. Adjacent
normal colonic mucosa was present in 65% of the 106 tumor
specimens on the array, permitting side-by-side comparisons of
immunostaining results for normal versus malignant epitheli-
um. In addition, four specimens of normal colon derived from
individuals who were not diagnosed with colon cancer were
stained separately.
Immunohistochemical analysis of tissue specimens on the
microarray chips revealed higher expression of caspase-14
protein, assessed by immunoscore, in normal colonic
epithelium compared with the invasive cancer (P = 0.01).
An opposite tendency was observed for PCNA immunostain-
ing, but statistical analysis did not reveal significant
difference between PCNA levels in normal versus malignant
epithelium. No correlations were observed in this cohort
between overall survival and caspase-14 protein content in
tumors. Age, gender, microsatellite instability status, and
anatomic location of tumors were not associated with
caspase-14 expression.
Ovarian cancer. Caspase-14 expression was investigated
using tissue microarrays containing tissue specimens from 91
ovarian carcinoma patients. For six of these patients, specimens
of normal ovarian surface epithelium or fallopian tube were
also available. The patient cohort comprised 62 individuals
with serous carcinomas and 29 cases of nonserous tumors,
including mucinous (n = 13), endometrioid (n = 11), clear cell
(n = 2), granulose (n = 1), dysgerminoma (n = 1), and
carcinosarcoma (n = 1) types. No significant differences in
Fig. 2. Immunohistochemical analysis of
caspase-14 expression in uterine cervix.
Representative caspase-14 immunostaining
results are presented showing cervical
specimens representing a continuum
from normal to malignant epithelium
(A, normal cervix; B, CIN1; C, CIN2;D,
CIN3; E, invasive carcinoma). Original
magnifications,100 to200. F, graphic
presentation of inverse correlations of
caspase-14 and PCNA immunostaining
during malignant progression in uterine
cervix. Means with error plots display the
distribution of immunopercentage data for
caspase-14 and PCNAwith respect to
progression of malignant transformation
and dedifferentiation of uterine cervix.
Points, mean immunopercentage; bars,
F1.96 SE from the mean.
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caspase-14 protein levels were noted between these two broad
histologic categories of ovarian cancer.
When separated into two groups based on stage, the
percentage of caspase-14 immunopositivity was significantly
higher in low stage carcinomas [Fe’de’ration Internationale des
Gynaecologistes et Obstetristes (FIGO) stage I + II] compared
with high-stage tumors (FIGO III and IV; P = 0.04; Fig. 4A-C).
Caspase-14 immunoscore data did not reach statistical signif-
icance (P = 0.08), but showed the same trend. In contrast to
caspase-14 immunostaining, PCNA immunopercentage was
slightly elevated in high-stage compared with low-stage tumors,
but the difference was statistically nonsignificant (Fig. 4C). No
correlation with caspase-14 expression data was observed for
patient age or histologic grade of tumor.
To correlate protein expression with clinical outcome,
immunostaining data for the investigated proteins were dichot-
omized into high versus low expression using median immu-
nopercentage or immunoscore as cutoffs. In univariate analysis,
significant correlations were observed in this cohort between
longer overall survival and higher caspase-14 immunopercent-
age (P = 0.03) and higher immunoscore (P = 0.04) data. In
contrast to overall survival, disease-free survival was not
significantly different between the two patient groups based on
caspase-14 expression. As tested by a Cox’s proportional hazards
model, high levels of caspase-14 were associated with reduced
risk of death from ovarian cancer, with hazard ratio data
suggesting a reduced relative risk of f40% (P = 0.03; Table 2).
However, in multivariate analysis, only histologic grade main-
tained independent prognostic significance (P = 0.002).
To select a more homogenous cohort of ovarian cancers, we
focused on the 62 serous carcinoma cases. The survival
advantage associated with higher caspase-14 immunostaining
was even more evident in this cohort (P = 0.006 for overall
survival; P = 0.02 for disease-free survival; Fig. 4D). Moreover,
in multivariate analysis of these serous carcinoma patients, the
outcome benefit of higher caspase-14 was maintained for
overall survival (P = 0.03 for caspase-14 immunopercentage;
P = 0.04 for immunoscore; Table 3 and data not shown).
Breast cancer. Tissue microarrays containing specimens
derived from 121 breast cancer patients were immunostained
for caspase-14. The tissue samples comprised 23 ductal
carcinoma in situ tumors, 103 ductal invasive, 15 lobular
invasive, and 3 mucinous invasive carcinoma specimens. In
addition, 16 normal mammary epithelium specimens, excised
from surgical margins, were included on the arrays, as well as
four independent samples of normal mammary gland tissue.
Unlike other tumors examined in this study, higher caspase-14
immunostaining was found in invasive cancers (P = 0.0008;
P = 0.0003; Fig. 5B) and in situ carcinomas (P = 0.003, P =
0.0004, respectively) compared with normal mammary epithe-
lium (Fig. 5A). Elevation of caspase-14 levels in transformed
Fig. 3. Distribution of caspase-14 and
PCNA immunostainings in gastric cancer.
Representative caspase-14 immunostaining
results are presented for microarrays of
gastric specimens in intestinal (A) and
diffuse (B) type of gastric adenocarcinoma.
C, distribution of immunopercentage data
for caspase-14 and PCNA in intestinal
versus diffuse cancers; points, means; bars,
SE. Caspase-14 immunoscore datawere
dichotomized into high (red) versus low
(blue) expression groups based on the
median values.The percentage of patients
remaining alive (Yaxis) was compounded
over time (X axis; in years) by the
Kaplan-Meier method (D).The log-rank
test was used for correlating the
immunostaining datawith the patient
survival.
Table 1. Multivariate Cox proportional hazards
analysis of markers in stage T3N0M0 gastric
carcinoma patients
Factors HR (95% CI) P
Caspase-14% 0.48 (0.2-0.9) 0.04
Recurrence 26.4 (11.9-58.6) <0.0001
NOTE: Tumor recurrence, cellular differentiation, histologic architecture, lym-
phocyte infiltration, mucin content, presence of signet ring cells, and immuno-
percentageof caspase-14were includedin theunivariate analysis.
Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval.
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mammary epithelium was accompanied by concomitant gain in
PCNA expression (r = 0.32, P < 0.0001 for immunopercentage;
r = 0.27, P = 0.001 for immunoscore; not shown). In addition to
ductal carcinoma in situ and invasive cancer, apocrine metapla-
sia and histologic lesions characterized as apocrine change
within sclerosing adenosis contained distinctly increased levels
of both caspase-14 and PCNA (data not shown). Thus,
elevations in caspase-14 seem to represent a very early alteration
in the pathogenesis of breast cancer.
No correlations were found between caspase-14 levels and
tumor size, node status, estrogen receptor or progesterone
receptor status or patient survival. However, caspase-14
expression was associated with histologic grade of tumors,
whereby high-grade tumors contained significantly higher
levels of this protein (84 F 2.1% versus 58 F 11.1%,
P = 0.0009, for immunopositivity; 148 F 6.8 versus 91 F
20.5, P = 0.02, for immunoscore).
Immunohistochemical analysis of caspase-14 protein in the
National Cancer Institute panel of tumor cell lines. The relative
levels of caspase-14 protein in the National Cancer Institute-
60 tumor cell line panel and additional prostate and breast
cancer cell lines were characterized by immunohistochemistry
analysis using a tissue microarray format. Figure 5C summa-
rizes arbitrary results showing the percentage immunopositiv-
ity data for caspase-14. Caspase-14 was detected at a
percentage of z10% in two of seven breast, two of six
ovarian, two of three prostate, four of seven colon, one of
eight renal, and three of eight lung cancer, two of seven
melanoma, two of six glioma, and one of six leukemia cell
lines. Automated imaging analysis of caspase-14 immunos-
taining (Fig. 5D) confirmed these results. Significant levels of
caspase-14, analyzed by immunoblotting, were previously
reported in human epithelial (prostate, breast, stomach, and
bladder) cancer cell lines (8).
Discussion
Caspase-14 expression was originally found in simple and
complex epithelia (8), and numerous reports linked this
protease to keratinocyte senescence (7, 10), suggesting a role
Fig. 4. Immunohistochemical analysis of
caspase-14 expression in ovarian cancers.
Representative caspase-14 immunostaining
results are presented in serous ovarian
cancer specimens derived from patients
with low (A) or high (B) stage tumors.
Original magnifications,100 or400.
C, means and error plots display
the distribution of caspase-14
immunopercentage in low-stage
(FIGOI + II) compared with high-stage
tumors (FIGOIII and IV). Points, mean
immunopercentage; bars, F1.96 SE from
themean.D, the percentage of patients
remaining alive (Yaxis) was compounded
over time (X axis; in years) by the
Kaplan-Meier method.The log-rank test
was used for correlating the caspase-14
immunoscore datawith the survival of
serous cancer patients.
Table 2. Univariate (A) and multivariate (B) Cox
proportional hazards analysis among patients with
ovarian cancer
Factors HR (95% CI) P
A
Stage 3.5 (1.1-11.3) 0.03
Grade 5.1 (1.8-14.8) 0.002
CA125 3.5 (1.1-10.9) 0.03
Age 1. 7 (1.0-2.7) 0.04
Caspase-14% 0.6 (0.3-0.9) 0.03
B
Grade 5.1 (1.8-14.5) 0.002
NOTE: All factors that showed prognostic significance in the univariate Cox
analysis were included in the multivariate Cox proportional hazards model.
Only significant results (P V 0.05) are presented in the table. Grade [low
(LMP + G1) high (G2 + G3)]; stage [low (I + II) high(III + IV)]; age cutoff
z60 years; CA125 cutoffz50 units/mL.
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for caspase-14 in epithelial cell differentiation. These findings
prompted us to investigate caspase-14 protein expression in
several types of epithelial malignancies. In this report, we
surveyed caspase-14 expression primarily by immunohisto-
chemistry methods in cervical, ovarian, breast, gastric, and
colon cancers. Our findings reveal alterations in caspase-14
expression in association with tumor pathogenesis and progres-
sion, with levels of caspase-14 immunostaining decreasing in
some malignant diseases (e.g., cervical, ovarian, and colorectal
cancers), whereas increasing in others (e.g., breast cancer). The
molecular events responsible for these tumor-associated alter-
ations in caspase-14 expression remain to be elucidated.
We observed a progressive loss of caspase-14 expression in
cervical cancer progression. Worldwide, cervical cancer is the
second most common neoplasm in women, accounting for
almost 12% of all female cancers (28). During reproductive
years, the endocervical columnar epithelium is transformed into
squamous epithelium, delineating the transformation (‘‘T’’)
zone in the region of the original squamocolumnar junction
(29). Chronic inflammation also contributes to the develop-
ment of the T zone, which eventually becomes the main site of
origin for premalignant lesions and invasive squamous cell
carcinomas of the cervix (29). Cervical cancers are believed to
arise through a stepwise progression that correlates with
histologic changes constituting a continuum from CINs (grades
Fig. 5. Distribution of caspase-14 immunostaining innormalmammary epithelium (A), invasive breast cancers (B), and a panel of 60 human cancer cell lines (C-D). A cell line
microarray slide was immunostained using AR-76 antibody.The histogram depicts percentage of caspase-14 immunopositivity in particular cell lines, as evaluated by visual
inspection (C) or using automated image capture and analysis system Ariol SL-50/MB-8TM (Applied Imaging, SanJose, CA;D).
Table 3. Univariate (A) and multivariate (B) Cox
proportional hazards analysis among patients with
serous cancer
Factors HR (95% CI) P
A
Grade 13.3 (1.8-96.2) 0.01
Caspase-14% 0.4 (0.2-0.8) 0.005
B
Grade 11.2 (1.5-82.0) 0.02
Caspase-14% 0.5 (0.3-0.9) 0.03
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1-3) to squamous cell carcinoma or adenocarcinoma of the
cervix (30).
Declining levels of caspase-14 observed during dedifferenti-
ation of cervical epithelium in the process of malignant
transformation parallel a reported function of this protein
during terminal maturation of epidermal keratinocytes (7, 10).
Recently, differential expression of caspase-14 in UV-induced
mouse skin squamous cell carcinomas compared with normal
skin was identified by serial analysis of gene expression profiling
(31). The subsequent Northern blot analysis revealed 8.5-fold
decrease of caspase-14 in squamous cell carcinomas (31). Thus,
our investigation uncovered a similar tendency in human cancer
derived from transformed cervical squamous epithelium. Also
in our study, PCNA, which is expressed in cells that have entered
the cell cycle, was dramatically increased with progressing
transformation in preneoplastic cervical lesions, inversely
correlating with caspase-14 expression. Thus, withdrawal from
the cell cycle and commitment to terminal differentiation may
be linked to pathways controlling caspase-14 expression.
Interestingly, a possible involvement of activated caspases in
terminal differentiation has been documented for a variety of
normal cell types, such as rodent lens epithelial cells, maturing
sperm cells, osteoblasts, and monocytes (32–35).
Gastric cancer is the second most frequent cause of death from
cancer in the world today. The Lauren’s classification recognizes
two distinct histologic types (i.e., intestinal and diffuse; ref. 36),
with the latter having a worse prognosis. In our investigation of
localized stomach cancers, caspase-14 was associated with well-
differentiated histology and the intestinal architecture, such that
caspase-14 staining was present at significantly higher levels in
well-differentiated intestinal tumors compared with poorly
differentiated diffuse cancers. Caspase-14 immunostaining also
conferred independent prognostic value for patients with
T3N0M0 stage disease, with retention of caspase-14 expression
associated with better survival. Thus, caspase-14 may provide a
useful marker for delineating differences in the clinical behavior
of gastric cancers, and therefore warrants further investigation
with respect to its potential prognostic utility.
The pathogenesis of intestinal-type gastric carcinomas is
believed to be promoted by chronic inflammation. In this
regard, gastric infection with Helicobacter pylori is causally
associated with chronic gastritis, atrophic gastritis, and intesti-
nal metaplasia. In this regard, based on a phylogenetic analysis,
the catalytic domain of caspase-14 is most closely akin to
caspase-1, caspase-4, and caspase-5 (2), which take part in the
intracellular activation of the proinflammatory cytokines
interleukin-1h and interleukin-18 (reviewed in ref. 37).
Considering the role of chronic inflammation in gastric cancer
pathogenesis, it is plausible that caspase-14 plays a role in the
generation of protective immunity against the bacterial
pathogens and chronic inflammation through effects on
cytokine production. Similar arguments could be made for
cervical cancer, which is often associated with chronic viral
infection with human papilloma virus. It remains to be
established, however, if caspase-14 proteolytically activates
proinflammatory cytokines.
In colorectal carcinoma patient cohort, caspase-14 levels
were significantly higher (P = 0.01) in normal colonic
epithelium compared with stage II adenocarcinoma. Unlike
gastric cancer, no associations were uncovered with clinico-
pathologic characteristics in the patient cohort we examined.
Normal ovarian epithelial cells contain abundant caspase-14
staining whereas cancers tend to lose expression of this
protease. We found an association between caspase-14
expression and low-stage disease (FIGO I and II), suggesting
that loss of caspase-14 expression is associated with progres-
sion of ovarian cancer. However, longitudinal studies are
required to determine whether loss of caspase-14 expression is
indicative of transformation of ovarian cancers to more
aggressive tumors.
In contrast to cervical, ovarian, gastric, and colorectal cancers,
elevated caspase-14 expression was found in invasive breast
cancers and ductal carcinoma in situ compared with normal
mammary epithelium (P = 0.01). The inverse correlation bet-
ween caspase-14 expression and differentiation seen in
neoplastic mammary gland tissue shows that caspase-14 is
not a global marker of cell differentiation. Although not
formally addressed here, it is also unlikely that caspase-14
expression is a general marker of growth arrest based on the
findings obtained for mammary gland lesions and gastric
cancers, as well as our finding of highly diverse expression of
caspase-14 in cultured cancer cell lines. Delineating the
mechanisms responsible for altered caspase-14 expression in
cancers may eventually provide insights into the tissue-specific
pathogenic mechanisms responsible for carcinogenesis and
uncover specific signaling pathways that govern the production
of this protease. Elucidating the biochemical and cellular
functions of caspase-14 may also provide new avenues for
understanding tumor biology and devising therapeutic
strategies.
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